Preliminary Study Of Maternal HLA-haploidentical Hematopoietic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (HSCT) is one of the treatments that can cure hematologic malignancies, but its use has been limited by the lack of appropriate HLA-matched donor in time. Virtually, most young patients have an HLA 2-antigen or 3-antigen incompatible relative who could server as a donor immediately. Besides technological advances, choosing the most appropriate donor is also an important factor to overcome the HLA barriers in haploidentical HSCT. Beacause mother is exposed to inherited paternal antigens (IPAs) of the fetus durinrg pregnancy and immunological tolerance may exist between the mother and fetus, mother might be a preferable stem cell donor. This subject is to explore the feasibility of maternal HLA-haploidentical HSCT for malignant hematological diseases through clinical and experimental studies.Objective: To explore the feasibility of maternal HLA-haploidentical HSCT for malignant hematological diseases, and to determine the significance of fetal microchimerism (FMc) in it. To establish an acute graft-versus-host disease (GVHD) model of murine H-2 haploidentical HSCT to evaluate the significancy of maternal HSCT.Method: 1. Clinical study of maternal HLA-haploidentical HSCT: 18 patients with hematologic malignancies underwent maternal HLA-haploidentical HSCT for at least one-locus mismatched. An ablative conditioning regimen along with...